meclizine has been researched along with Achondroplasia in 5 studies
Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.
Achondroplasia: An autosomal dominant disorder that is the most frequent form of short-limb dwarfism. Affected individuals exhibit short stature caused by rhizomelic shortening of the limbs, characteristic facies with frontal bossing and mid-face hypoplasia, exaggerated lumbar lordosis, limitation of elbow extension, GENU VARUM, and trident hand. (Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim, MIM#100800, April 20, 2001)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Long-term administration of meclizine 12." | 7.30 | Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia. ( Imagama, S; Kamiya, Y; Kato, D; Kitoh, H; Matsushita, M; Mishima, K; Nishida, K; Sawamura, K; Takemoto, G; Ueno, S; Yasuhiro, N, 2023) |
| "Meclizine was well tolerated in ACH children with no serious adverse events." | 6.94 | Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ( Ishiguro, N; Kamiya, Y; Kitoh, H; Kuwatsuka, Y; Matsushita, M; Mishima, K; Morikawa, H; Nagata, T; Nakai, Y; Ueda, K, 2020) |
| " Long-term administration of meclizine 12." | 3.30 | Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia. ( Imagama, S; Kamiya, Y; Kato, D; Kitoh, H; Matsushita, M; Mishima, K; Nishida, K; Sawamura, K; Takemoto, G; Ueno, S; Yasuhiro, N, 2023) |
| "Meclizine was well tolerated in ACH children with no serious adverse events." | 2.94 | Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia. ( Ishiguro, N; Kamiya, Y; Kitoh, H; Kuwatsuka, Y; Matsushita, M; Mishima, K; Morikawa, H; Nagata, T; Nakai, Y; Ueda, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsushita, M | 5 |
| Kitoh, H | 5 |
| Mishima, K | 4 |
| Kamiya, Y | 2 |
| Kato, D | 1 |
| Takemoto, G | 1 |
| Sawamura, K | 1 |
| Ueno, S | 1 |
| Yasuhiro, N | 1 |
| Nishida, K | 1 |
| Imagama, S | 1 |
| Nagata, T | 1 |
| Ueda, K | 1 |
| Kuwatsuka, Y | 1 |
| Morikawa, H | 1 |
| Nakai, Y | 1 |
| Ishiguro, N | 4 |
| Esaki, R | 1 |
| Ohno, K | 3 |
| Ohkawara, B | 2 |
| Kaneko, H | 1 |
| Ito, M | 1 |
| Masuda, A | 2 |
| Hasegawa, S | 1 |
| Mori, K | 1 |
| Yasoda, A | 1 |
2 trials available for meclizine and Achondroplasia
| Article | Year |
|---|---|
Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia.
Topics: Achondroplasia; Animals; Area Under Curve; Bone Development; Drug Repositioning; Meclizine; Mice | 2023 |
Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
Topics: Achondroplasia; Administration, Oral; Animals; Child; Child, Preschool; Dose-Response Relationship, | 2020 |
3 other studies available for meclizine and Achondroplasia
| Article | Year |
|---|---|
Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Topics: Achondroplasia; Animals; Bone and Bones; Bone Development; Cancellous Bone; Disease Models, Animal; | 2017 |
Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Topics: Achondroplasia; Amino Acid Substitution; Animals; Cell Differentiation; Cell Proliferation; Cells, C | 2013 |
Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Topics: Achondroplasia; Animals; Bone Development; Female; Histamine H1 Antagonists; In Vitro Techniques; Ma | 2015 |